Loss of GSTM1 in AASK was associated with increased risk of CKD progression (HR 0 copy: HR 1.88; 95% CI: 1.07–3.30; HR 1 copy: 1.68; 95% CI: 1.00–2.84). This evidence concerns the gene GSTM1 and chronic kidney disease.